Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients

Blood. 2016 Jan 21;127(3):360-2. doi: 10.1182/blood-2015-08-662130. Epub 2015 Nov 13.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cladribine / administration & dosage
  • Cytarabine / administration & dosage
  • Daunorubicin / administration & dosage
  • Gene Duplication*
  • Humans
  • Karyotype*
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics*
  • Leukemia, Myeloid, Acute / mortality
  • Treatment Outcome
  • fms-Like Tyrosine Kinase 3 / genetics*

Substances

  • Cytarabine
  • Cladribine
  • fms-Like Tyrosine Kinase 3
  • Daunorubicin